A Multicentre, Randomised, Double Blind, Parallel Design, Placebo Controlled Study to Evaluate the Efficacy and Safety of Uthever (NMN Supplement), an Orally Administered Supplementation in Middle Aged and Older Adults
The goal of this research was to test the stability and effectiveness of Uthever, a nicotinamide mononucleotide (NMN) supplementation, in stimulating NAD+ synthesis in middle-aged as well as older individuals, and therefore its anti-ageing impact in 66 mature adults and senior volunteers.
HOMA IR Index (Homeostatic Model Assessment for Insulin Resistance): Investigates the anti-ageing impact on insulin control approaching normalization.
SF-36 questionnaire (36-Item Short Form Survey): This test displays the participant's well-being. The greater the score, the greater the participants' health.
Placebo effect/arm: A phenomenon whereby some patients benefit from the use of an inert substitute drug or therapy.
In both groups, there was no clinically relevant malfunction in safety diagnostic procedures, indicating the safety of Uthever (NMN) supplement. The rise in NAD+/NADH concentrations in blood, as well as the overall enhancement in general health including walking stamina, are all clinically significant.
Purpose of study
The clinical study's goal was to assess the anti-ageing impact of NMN together with its feasibility within a double-blind, paralleled, randomized clinical trial.
The study was meant to strengthen the evidence currently available for NMN's effectivity. The current study strategy relies on pre-clinical evidence for NMN administration.
The trial included 66 healthy volunteers aged 40 to 65 who were directed to consume two pills (each containing 150 mg of NMN or starch powder) once a day following breakfast over a period of 60 days.
At day 30, NAD+/NADH levels in the serum increased significantly, by 11.3%, meanwhile the placebo arm exhibited no change. The conclusion of the study on day 60, NAD+/NADH concentrations had elevated by 38% versus the baseline, contrasted to 14.3% inside the placebo arm. The difference between the two arms (placebo and active) were not statistically significant yet led to an increase of NAD+ concentration within the serum after a period of 2 months.
In the case of the SF 36, the Uthever arm increased by 6.5% at day 60, while the placebo arm increased by 3.4%. Though the statistical difference was not significant, the overall increase of the scores was double in the placebo arm.
HOMA IR Index:
The mean HOMA IR Index increased by 0.6% in the Uthever arm and 30.6% throughout the Placebo arm towards the conclusion of the research. The statistical difference was not significant among the arms.